FGF-23 Antibody [FG322-3] | 36-075

FGF-23 Antibody [FG322-3] | 36-075 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human FGF-23.

Research Area: Obesity

Tested Application: E, IHC, WB

Application: ELISA: (direct and indirect: 1:2, 000-1:5, 000) . Immunohistochemistry: (paraffin sections (1:100-1:500) ) . Western Blot: (1:2, 000-1:5, 000 using ECL. Suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at room temperature) . Optimal conditions must be determined individually for each application.

Specificiy: Recognizes human FGF-23. Does not cross-react with mouse FGF-23.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: FG322-3

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. 0.2um-filtered solution in PBS, pH 7.4. Contains no preservatives.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.

Alternate Name: Fibroblast Growth Factor 23; Tumor-derived Hypophosphatemia-inducing Factor

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: FGF-23 is a regulator of phosphate homeostasis. It upregulates EGR1 expression in the presence of KLBy. Acts directly on the parathyroid to decrease PTH secretion. Regulates the vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Defects in FGF-23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) and of hyperphosphatemic familial tumoral calcinosis (HFTC) .